Genmab — September 2020
-
08:23 isa/Pom/dex head to head studie blev ikke kørt mod dara/pom/dex. Så derfor kan man ikke konkludere at isa er bedre end dara
-
Bryan Garnier: Sell rating confirmed and TP decreased to DKK2000
-
-
Handelsbanken: http://prntscr.com/unlhzj
-
GENMAB A/S GMAB.CO: GUGGENHEIM RAISES PRICE TARGET TO DKK 2684 FROM DKK 2568 - Reuters News
-
ØU er nu meget bullish på casen?
-
Vi fik vist reddet lidt af æren i dag på en uge, der ændrede noget af grundforståelsen af GEN/JJ forholdet. Pensionisten ramte den vist lige bagi med hvad der må være kandidaten til årets citat: “ Katastrofen blev vendt til en møgdag ;-)”
-
Det har du faktisk ret i. Tror dog ikke det er en bevidst handling.

-
NBI +2,18%
-
Efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials https://twitter.com/mtmdphd/status/1309129398990385153?s=21
-
God morgen.

-
Daratumumab (anti-CD38) for treatment of disseminated nontuberculous mycobacteria in a patient with anti-IFN-γ autoantibodies https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1086/5880009
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind

